Prophylaxis in the haemophilia population

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 181-188

  Blanchette, V S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Haemophilia; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; FOLLOW UP; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HUMAN; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION;

ADOLESCENT; BLOOD COAGULATION FACTORS; CHILD; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; RISK FACTORS; YOUNG ADULT;

EID: 77955028666     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02318.x     Document Type: Article

References (46)

1. The Concise Oxford Dictionary 1982, 7th edn, Oxford, Oxford University Press
2. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004, 10(Suppl. 4):97-104.
3. van den Berg HM, Dunn A, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. Haemophilia 2006, 12(Suppl. 3):159-68.
4. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008, 14(Suppl. 3):196-201.
5. Berntorp E, Astermark J, Björkman S. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003, 9(Suppl. 1):1-4.
6. Donadel-Claeyssens S. Meeting Report. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006, 12:124-7.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
8. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994, 236:391-9.
9. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg 1977, 59-A:287-305.
10. Ahlberg Å. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965, 77(Suppl. 1):1-98.
11. Roosendaal G, Lafeber FPJG. Blood-induced joint damage in hemophilia. Semin Thromb Hemost 2003, 29:37-42.
12. Valentino LA, Hakobyan N, Rodriguez N, Hoots WK. Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage. Haemophilia 2007, 13(Suppl. 3):10-3.
13. Hoots WK, Rodriguez N, Boggio L, Valentino LA. Pathogenesis of haemophilic synovitis: clinical aspects. Haemophilia 2007, 13(Suppl. 3):4-9.
14. Valentino LA, Hakobyan N, Enockson C. Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory singals and angiogenic clues. Semin Hematol 2008, 45(Suppl. 1):S50-7.
15. Hooiveld MJJ, Roosendaal G, Vianen ME. Immature articular cartilage is more susceptible to blood-induced damage than mature articular cartilage. An in vivo animal study. Arthritis Rheum 2003, 48:396-403.
16. Feldman BM, Pai M, Rivard GE. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006, 4:1228-36.
17. Monroe DM, Mackman N, Hoffman M. Wound healing in hemophilia B mice and low tissue factor mice. Thromb Res 2010, 125:574-7.
18. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatement in severe haemophilia A and B. J Intern Med 1992, 232:25-32.
19. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997, 241:395-400.
20. Fischer K, van de Bom JG, Molho P. Prophylactic versus on-demand treatment strategies was in for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002, 8:745-52.
21. Fischer K, Astermark J, van der Bom JG. Prophylaxis treatment for severe haemophilia: comparsion of an intermediate-dose to a high-dose regimen. Haemophilia 2002, 8:753-60.
22. Blanchette VS, Babyn P, Chan A. Long term (10 year) results from the Canadian hemophilia primary prophylaxis study. J Thromb Haemost 2009, 7(Suppl. 2):54-5.
23. Astermark J, Petrini P, Tengborn L. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999, 105:1109-13.
24. Fischer K, van der Bom JG, Mauser-Bunschoten EP. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002, 99:2337-41.
25. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe hemophilia A and B? Haemophilia 2001, 7:99-102.
26. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003, 9(Suppl. 1):101-10.
27. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6 year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004, 10:689-97.
28. Collins PW, Blanchette VS, Fischer K. Break-through bleeding in relation to predicted factor VIII levels in patients recurring prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009, 7:413-20.
29. Kern M, Blanchette V, Stain AM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr 2004, 145:628-34.
30. Collins PW, Björkman S, Fischer K. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010, 8:269-75.
31. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993, 51:247-52.
32. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemphilia 1997, 3:96-101.
33. Carlsson M, Björkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998, 4:83-8.
34. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010, e-published 9 February
35. Hay CRM. Prophylaxis in adults with haemophilia. Haemophilia 2007, 13(Suppl. 2):10-5.
36. Richards M, Altisent C, Batorova A. Should prophylaxis be used in adolescent and adult patients with severe haemophilia A: an European survey of practice and outcome data. Haemophilia 2007, 13:473-9.
37. Biss T, Chan AK, Blanchette VS. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008, 14:923-30.
38. Fischer K, van der Bom JG, Prejs R. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001, 7:544-50.
39. van Dijk K, Fischer K, van der Bom JG. Can long-term prophylaxis for severe hemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005, 130:107-12.
40. Collins P, Faradji A, Morfini M. Efficacy and safety of secondary prophylaxis vs on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month cross over study. J Thromb Haemost 2010, 8:83-9.
41. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years. A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009, 65:989-98.
42. Björkman S, Blanchette VS, Fischer K. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010, 8:269-75.
43. Fischer K, van der Bom JG, Mauser-Bunschoten EP. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001, 7:446-52.
44. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006, 2:1-26.
45. Tagliaferri A, Franchini M, Coppola A. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008, 14:945-51.
46. Feldman BM, Funk S, Lundin B. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia 2008, 14(Suppl. 3):162-9.